
Isabelle Fajac

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3129047/publications.pdf Version: 2024-02-01



ISARELLE FAIAC

#	Article	IF	CITATIONS
1	Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respiratory Medicine,the, 2014, 2, 539-547.	5.2	301
2	Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 284-291.	0.3	34
3	Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor. European Respiratory Journal, 2016, 48, 249-252.	3.1	30
4	Insights into the variability of nasal potential difference, a biomarker of CFTR activity. Journal of Cystic Fibrosis, 2020, 19, 620-626.	0.3	14
5	Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection. Journal of Cystic Fibrosis, 2021, 20, 1010-1017.	0.3	11
6	Persistent Nasal Inflammation 5 Months after Acute Anosmia in Patients with COVID-19. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1319-1322.	2.5	10
7	Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 1026-1034.	0.3	9
8	Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization. Pulmonary Therapy, 2021, 7, 455-468.	1.1	8
9	Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 1018-1025.	0.3	5
10	A new Clinical Trials Directive to boost academic trials?. Lancet Respiratory Medicine,the, 2013, 1, 99-101.	5.2	3